marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2025-Q3
added 11-03-2025
Exact Sciences Corporation EBITDA 2011-2025 | EXAS
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Exact Sciences Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -757 M | 46.6 M | -493 M | -761 M | -698 M | -218 M | -136 M | -103 M | -157 M | -155 M | -98.9 M | -45.3 M | -51.7 M | -28.4 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 46.6 M | -761 M | -261 M |
Quarterly EBITDA Exact Sciences Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.16 M | 29 M | -66 M | - | -9.1 M | 3.44 M | -76.1 M | - | 36.1 M | -49.4 M | -50.3 M | - | -113 M | -134 M | -154 M | - | -140 M | -150 M | -280 M | - | -150 M | -33.4 M | -66.4 M | -82.3 M | -13.8 M | -20.4 M | -61.7 M | -48.6 M | -26.6 M | -23.9 M | -32.2 M | -23 M | -27.8 M | -31.1 M | -35.4 M | -37.7 M | -38.1 M | -45 M | -45.4 M | -40.4 M | -43.3 M | -39.4 M | -34.4 M | -32.6 M | -29.9 M | -18.2 M | -15.5 M | -12.3 M | -10.3 M | -11.7 M | -10.6 M | -14 M | -12.3 M | -14.5 M | -10.5 M | -9.94 M | -7.58 M | -6.5 M | -4.34 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 36.1 M | -280 M | -43.9 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Diagnostics research industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
-46 M | $ 0.33 | -6.23 % | $ 30.6 M |  Germany |
 |
Fluidigm Corporation
FLDM
|
-35.1 M | $ 3.75 | 1.08 % | $ 308 M |  USA |
 |
Global Cord Blood Corporation
CO
|
652 M | $ 2.99 | - | $ 399 M |  China |
 |
Oxford Immunotec Global PLC
OXFD
|
-3.26 M | $ 21.99 | - | $ 562 M |  Britain |
 |
Genetron Holdings Limited
GTH
|
-518 M | $ 4.03 | 0.12 % | $ 80.1 M | China |
 |
Chembio Diagnostics
CEMI
|
-21.1 M | $ 0.46 | 0.22 % | $ 16.8 M | USA |
 |
Pacific Biosciences of California
PACB
|
-323 M | $ 2.23 | -4.91 % | $ 566 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
553 M | $ 27.4 | 0.31 % | $ 20 B |  Niderland |
 |
Meridian Bioscience
VIVO
|
70.9 M | $ 33.97 | - | $ 1.49 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-20.2 M | $ 0.48 | -20.0 % | $ 1.06 M | USA |
 |
Quidel Corporation
QDEL
|
1.11 B | $ 27.64 | 2.39 % | $ 1.16 B | USA |
 |
Quotient Limited
QTNT
|
-73.9 M | $ 0.32 | -11.32 % | $ 1.1 M |  Schweiz |
 |
Bioventus
BVS
|
-24.4 M | $ 6.58 | 0.38 % | $ 412 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
416 M | $ 165.21 | - | $ 10.7 B | USA |
 |
Thermo Fisher Scientific
TMO
|
8.49 B | $ 564.29 | -0.48 % | $ 216 B | USA |
 |
Twist Bioscience Corporation
TWST
|
-189 M | $ 31.45 | -4.38 % | $ 1.82 B | USA |
 |
Heska Corporation
HSKA
|
-6.33 M | $ 119.99 | - | $ 1.31 B | USA |
 |
Motus GI Holdings
MOTS
|
-11.5 M | $ 0.17 | -34.28 % | $ 263 K |  Israel |
 |
Biocept
BIOC
|
-30.3 M | $ 0.43 | -13.05 % | $ 7.29 M | USA |
 |
Syneos Health
SYNH
|
625 M | $ 42.98 | - | $ 4.46 B | USA |
 |
Invitae Corporation
NVTA
|
47.2 M | $ 0.09 | - | $ 21.2 M | USA |
 |
DermTech
DMTK
|
-104 M | $ 0.09 | -11.32 % | $ 2.94 M | USA |
|
Akumin
AKU
|
70.1 M | $ 0.29 | -17.87 % | $ 25.9 M |  Canada |
 |
Castle Biosciences
CSTL
|
24.7 M | $ 25.99 | 1.9 % | $ 722 M | USA |
 |
DarioHealth Corp.
DRIO
|
-55.7 M | $ 13.51 | -3.43 % | $ 383 M | Israel |
 |
Exagen
XGN
|
-20.6 M | $ 11.86 | 1.63 % | $ 210 M | USA |
 |
PerkinElmer
PKI
|
775 M | $ 115.24 | -0.91 % | $ 14.7 B | USA |
 |
OpGen
OPGN
|
499 K | $ 1.96 | -16.95 % | $ 1.54 M | USA |
 |
DexCom
DXCM
|
784 M | $ 59.78 | 2.68 % | $ 23.1 B | USA |
 |
Organovo Holdings
ONVO
|
-12.4 M | $ 2.12 | -2.3 % | $ 19.4 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
-749 M | $ 12.18 | -9.51 % | $ 131 M | China |
 |
Danaher Corporation
DHR
|
5.58 B | $ 214.2 | -0.55 % | $ 157 B | USA |
 |
Neogen Corporation
NEOG
|
-942 M | $ 6.26 | 1.46 % | $ 1.36 B | USA |
 |
Biomerica
BMRA
|
-5.05 M | $ 2.71 | -0.52 % | $ 6.23 M | USA |
 |
Fulgent Genetics
FLGT
|
-49 M | $ 22.96 | 2.25 % | $ 694 M | USA |
 |
Psychemedics Corporation
PMD
|
-1.22 M | $ 2.67 | -1.84 % | $ 15.3 M | USA |
 |
Genetic Technologies Limited
GENE
|
-6 M | $ 0.77 | - | $ 7.1 B |  Australia |
 |
Myriad Genetics
MYGN
|
-62.3 M | $ 8.03 | -0.19 % | $ 728 M | USA |
 |
Renalytix AI plc
RNLX
|
-29.2 M | $ 0.21 | 5.66 % | $ 22.7 M | Britain |
 |
Medpace Holdings
MEDP
|
475 M | $ 596.13 | 1.92 % | $ 18.5 B | USA |
 |
IQVIA Holdings
IQV
|
3.32 B | $ 214.25 | -1.05 % | $ 38.8 B | USA |
 |
CareDx, Inc
CDNA
|
-189 M | $ 14.61 | -2.6 % | $ 786 M | USA |
 |
Brainsway Ltd.
BWAY
|
-5 M | $ 17.58 | 4.3 % | $ 99.4 M | Israel |
|
Biodesix
BDSX
|
-28.7 M | $ 6.33 | -7.3 % | $ 821 M | USA |
 |
T2 Biosystems
TTOO
|
-48.8 M | $ 0.12 | -39.35 % | $ 313 K | USA |
 |
OPKO Health
OPK
|
-53.9 M | $ 1.42 | 4.04 % | $ 986 M | USA |
 |
Guardant Health
GH
|
-401 M | $ 98.46 | 5.84 % | $ 12.1 B | USA |
 |
Agilent Technologies
A
|
1.67 B | $ 144.14 | -1.5 % | $ 43.8 B | USA |
 |
Trinity Biotech plc
TRIB
|
6.62 M | $ 1.0 | - | $ 61.9 M |  Irlanda |
 |
Co-Diagnostics
CODX
|
-41.5 M | $ 0.41 | -10.11 % | $ 12 M | USA |